<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101525337</journal-id>
<journal-id journal-id-type="pubmed-jr-id">37346</journal-id>
<journal-id journal-id-type="nlm-ta">ACS Chem Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">ACS Chem Neurosci</journal-id>
<journal-title-group>
<journal-title>ACS chemical neuroscience</journal-title>
</journal-title-group>
<issn pub-type="epub">1948-7193</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30511829</article-id>
<article-id pub-id-type="pmc">6512341</article-id>
<article-id pub-id-type="doi">10.1021/acschemneuro.8b00600</article-id>
<article-id pub-id-type="manuscript">NIHMS1026589</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kozikowski</surname>
<given-names>Alan P.</given-names>
</name>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="aff" rid="A1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shen</surname>
<given-names>Sida</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0295-2545</contrib-id>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="author-notes" rid="FN4">○</xref>
<xref ref-type="author-notes" rid="FN1">◆</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pardo</surname>
<given-names>Marta</given-names>
</name>
<xref ref-type="aff" rid="A3">§</xref>
<xref ref-type="author-notes" rid="FN4">○</xref>
<xref ref-type="author-notes" rid="FN2">¶</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tavares</surname>
<given-names>Maurício T.</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4400-7787</contrib-id>
<xref ref-type="aff" rid="A2">‡</xref>
<xref ref-type="author-notes" rid="FN3">+</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Szarics</surname>
<given-names>Dora</given-names>
</name>
<xref ref-type="aff" rid="A4">∥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Benoy</surname>
<given-names>Veronick</given-names>
</name>
<xref ref-type="aff" rid="A5">⊥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zimprich</surname>
<given-names>Chad A.</given-names>
</name>
<xref ref-type="aff" rid="A6">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kutil</surname>
<given-names>Zsófia</given-names>
</name>
<xref ref-type="aff" rid="A7">∇</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Guiping</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9818-4773</contrib-id>
<xref ref-type="aff" rid="A2">‡</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bařinka</surname>
<given-names>Cyril</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2751-3060</contrib-id>
<xref ref-type="aff" rid="A7">∇</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Robers</surname>
<given-names>Matthew B.</given-names>
</name>
<xref ref-type="aff" rid="A6">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Van Den Bosch</surname>
<given-names>Ludo</given-names>
</name>
<xref ref-type="aff" rid="A5">⊥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eubanks</surname>
<given-names>James H.</given-names>
</name>
<xref ref-type="aff" rid="A4">∥</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jope</surname>
<given-names>Richard S.</given-names>
</name>
<xref ref-type="aff" rid="A3">§</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>†</label>StarWise Therapeutics LLC, Madison, Wisconsin 53719, United States</aff>
<aff id="A2"><label>‡</label>Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, United States</aff>
<aff id="A3"><label>§</label>Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida 33136, United States</aff>
<aff id="A4"><label>∥</label>Division of Genetics and Development, Krembil Research Institute, University Health Network, Toronto, Ontario M5G 2C4, Canada</aff>
<aff id="A5"><label>⊥</label>Laboratory of Neurobiology, Center for Brain &amp; Disease (VIB) and Leuven Brain Institute (LBI), KU Leuven, B-3000 Leuven, Belgium</aff>
<aff id="A6"><label>#</label>Promega Corporation, Madison, Wisconsin 53711, United States</aff>
<aff id="A7"><label>∇</label>Laboratory of Structural Biology, Institute of Biotechnology of the Czech Academy of Sciences, Prumyslova 595, 252 50 Vestec, Czech Republic</aff>
<author-notes>
<fn fn-type="present-address" id="FN1">
<label>◆</label>
<p id="P1">Present Addresses</p>
<p id="P2">S.S.: Departments of Chemistry and Molecular Biosciences, Chemistry of Life Processes Institute, Center for Molecular Innovation and Drug Discovery, and Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois 60208, United States.</p>
</fn>
<fn fn-type="present-address" id="FN2">
<label>¶</label>
<p id="P3">M.P.: Department of Neurology, Miller School of Medicine, University of Miami, Miami, FL 33136, United States.</p>
</fn>
<fn fn-type="present-address" id="FN3">
<label>+</label>
<p id="P4">M.T.T: Faculty of Pharmaceutical Sciences, Department of Pharmacy, University of São Paulo, São Paulo, Brazil.</p>
</fn>
<fn fn-type="con" id="FN4">
<label>○</label>
<p id="P5">Author Contributions</p>
<p id="P6">S.S. and M.P. contributed equally to this paper. StarWise Therapeutics LLC: A.P.K. conceived the original idea, initiated the project, and oversaw all the experimental design and data analysis. University of Illinois at Chicago: S.S. designed and synthesized compounds, oversaw all the experimental design, analyzed data, and wrote the manuscript with assistance from the other authors; M.T.T. synthesized compounds, performed the docking studies, and assisted in the preparation of the manuscript; G.Z. synthesized some of the reported compounds. University of Miami: M.P. designed and performed the in vivo FXS mice model studies and assisted in the preparation of the manuscript, R.S.J. oversaw the experimental design and data analyses of animal studies. University Health Network: D.S. designed and performed the dose—response tubulin acetylation studies in HEK293 cells and assisted in the preparation of the manuscript, and J.H.E. oversaw the experimental design and data analyses of the in vitro tubulin acetylation study. Leuven Research Institute for Neuroscience and Disease: V.B. designed and performed the tubulin/histone acetylation studies in N2a and assisted in the preparation of the manuscript; L.V.D.B. oversaw the experimental design and data analyses of the in vitro tubulin acetylation study. Promega Corporation: C.A.Z. designed and performed the cellular HDAC target engagement assay; M.B.R. oversaw the experimental design and data analyses of target engagement study and assisted in the preparation of the manuscript. Institute of Biotechnology of the Czech Academy of Sciences: Z.K. performed and confirmed the HDAC6 and HDAC11 data for SW-100. C.B. oversaw the experimental design and data analyses of HDAC enzyme studies.</p>
</fn>
<corresp id="CR1"><label>*</label><bold>Corresponding Author:</bold><email>akozikowski@starwisetrx.com</email>. Phone: 773-793-5866.</corresp>
<fn fn-type="COI-statement" id="FN6">
<p id="P72">The authors declare the following competing financial interest(s): A.P.K. is the owner of StarWise Therapeutics LLC and thus declares potential financial interests as does G.Z. who is employed by StarWise Therapeutics.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>2</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>14</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>20</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>3</month>
<year>2020</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>1679</fpage>
<lpage>1695</lpage>
<!--elocation-id from pubmed: 10.1021/acschemneuro.8b00600-->
<abstract id="ABS1">
<p id="P7">Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures. Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacological and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, <italic>Fmr1</italic><sup><italic>−/−</italic></sup> mice. This small molecule demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC<sub>50</sub> = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms. Moreover, through its inhibition of the <italic>α</italic>-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates <italic>α</italic>-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated <italic>α</italic>-tubulin levels in the hippocampus of <italic>Fmr1</italic><sup><italic>−/−</italic></sup> mice. Lastly, SW-100 ameliorates several memory and learning impairments in <italic>Fmr1</italic><sup><italic>−/−</italic></sup> mice, thus modeling the intellectual deficiencies associated with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.</p>
</abstract>
<abstract abstract-type="graphical" id="ABS2">
<title>Graphical Abstract</title>
<p id="P8">
<graphic orientation="portrait" position="anchor" xlink:href="nihms-1026589-f0001.jpg"></graphic>
</p>
</abstract>
<kwd-group>
<kwd>Phenylhydroxamate</kwd>
<kwd>permeability</kwd>
<kwd>Ames negative</kwd>
<kwd>acetylated α-tubulin</kwd>
<kwd>memory and learning impairments</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>